Literature DB >> 8254326

A dimensional and categorical approach to the symptomatology of recent-onset schizophrenia.

A J Van der Does1, D H Linszen, P M Dingemans, M A Nugter, W F Scholte.   

Abstract

Sixty-five patients with recent-onset schizophrenia were assessed with two widely used symptom scales, the Brief Psychiatric Rating Scale-Expanded (BPRS-E) and the Psychiatric Assessment Scale (Manchester scale). Principal components analysis of the BPRS-E scores yielded a four-dimensional structure: positive symptoms, negative symptoms, disorganization, and depression. With the Psychiatric Assessment Scale, three dimensions were found: the positive symptoms (delusions, hallucinations) and disorganization (incoherence) appeared in one dimension. A categorical analysis resulted in predominantly positive, negative, and disorganized clusters, but more than half of the sample could not be allocated to any of these groups.

Entities:  

Mesh:

Year:  1993        PMID: 8254326     DOI: 10.1097/00005053-199312000-00006

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  10 in total

Review 1.  Symptom dimensions in the course of childhood-onset schizophrenia.

Authors:  D Bunk; C Eggers; M Klapal
Journal:  Eur Child Adolesc Psychiatry       Date:  1999       Impact factor: 4.785

2.  The Brief Psychiatric Rating Scale (version 4.0) factorial structure and its sensitivity in the treatment of outpatients with unipolar depression.

Authors:  Adriano Zanello; Laurent Berthoud; Joseph Ventura; Marco C G Merlo
Journal:  Psychiatry Res       Date:  2013-07-26       Impact factor: 3.222

3.  Component structure of the expanded Brief Psychiatric Rating Scale (BPRS-E).

Authors:  P M Dingemans; D H Linszen; M E Lenior; R M Smeets
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

4.  Factor structure of the BPRS in deaf people with schizophrenia: correlates to language and thought.

Authors:  Heather K Horton; Steven M Silverstein
Journal:  Cogn Neuropsychiatry       Date:  2011-04-08       Impact factor: 1.871

5.  Symptom dimensions as predictors of clinical outcome, duration of hospitalization, and aggressive behaviours in acutely hospitalized patients with psychotic exacerbation.

Authors:  Alessandro Colasanti; Silvia Paletta; Donatella Moliterno; Alessandra Mazzocchi; Massimo Carlo Mauri; Alfredo Carlo Altamura
Journal:  Clin Pract Epidemiol Ment Health       Date:  2010-08-09

6.  EEG alpha coherence and psychopathological dimensions of schizophrenia.

Authors:  John P John; Sumant Khanna; N Pradhan; C R Mukundan
Journal:  Indian J Psychiatry       Date:  2002-04       Impact factor: 1.759

7.  Intrinsic motivation as a mediator of relationships between symptoms and functioning among individuals with schizophrenia spectrum disorders in a diverse urban community.

Authors:  Ann-Marie Yamada; Karen K Lee; Tam Q Dinh; Concepción Barrio; John S Brekke
Journal:  J Nerv Ment Dis       Date:  2010-01       Impact factor: 2.254

8.  Clustering of Schizotypal Features in Unaffected First-Degree Relatives of Schizophrenia Patients.

Authors:  Simon S Y Lui; Karen S Y Hung; Yi Wang; Karen K Y Ho; Hera K H Yeung; Ya Wang; Jia Huang; Diane C Gooding; Eric F C Cheung; Raymond C K Chan
Journal:  Schizophr Bull       Date:  2018-10-15       Impact factor: 9.306

9.  Neurocognitive abnormalities during comprehension of real-world goal-directed behaviors in schizophrenia.

Authors:  Tatiana Sitnikova; Donald Goff; Gina R Kuperberg
Journal:  J Abnorm Psychol       Date:  2009-05

10.  Mismatch Negativity and P3a Impairment through Different Phases of Schizophrenia and Their Association with Real-Life Functioning.

Authors:  Giulia M Giordano; Luigi Giuliani; Andrea Perrottelli; Paola Bucci; Giorgio Di Lorenzo; Alberto Siracusano; Francesco Brando; Pasquale Pezzella; Michele Fabrazzo; Mario Altamura; Antonello Bellomo; Giammarco Cascino; Anna Comparelli; Palmiero Monteleone; Maurizio Pompili; Silvana Galderisi; Mario Maj
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.